Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for RIVAROXABAN
- Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
- RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing
- Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
- Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
- Rivaroxaban Monotherapy After CYP2C19 Genotype Testing in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention
- Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
- Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus
- VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
- DOAC in Patients With Child B Liver Cirrhosis
- Perioperative Management of Factor Xa Inhibitors
- Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation
- Anticoagulation in Post MI LV Thrombus Trial in Nepal
- HIP Fracture Oral thromboPROphylaxis (Hip PRO Pilot)
- Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty
- Efficacy and Safety of Low Dose Rivaroxaban in Patients With Anterior Myocardial Infarction
- THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
- PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers
- Coronary Artery Ectasia, Efficacy of Various Anti Thrombotic Regimens.
- Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI
- Efficacy of Direct Oral Anticoagulants as a Prophylactic Anticoagulation of Catheter Induced Thrombosis
- Anticoagulant Using Rivaroxaban on Top of Aspirin Versus Antiplatelet Therapy in Intracranial Atherostenosis Stenosis
- Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion
- Rivaroxaban Versus Warfarin for Thromboprophylaxis in Children With Giant Coronary Aneurysms After Kawasaki Disease
- NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
- To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome
- Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
- Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events
- Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects
- Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk
- Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty
- BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects
- Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients
- Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)
- Outcomes of Rivaroxaban and Aspirin in PAD After Endovascular Revascularization
- Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal Cancer
- Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery
- Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia
- Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
- Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
- Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
- Effects of Edoxaban on Platelet Aggregation
- Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
- Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
- AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
- THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
- Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
- Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin
- Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease
- WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?
- The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
- DOT HeartMate 3 Study
- Rivaroxaban in Left Ventricular Thrombus
- An Exploratory Study of Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants Rivaroxaban in Patients With Left Ventricular Thrombus
- Prophylactic vs Therapeutic Anticoagulation in Symptomatic Isolated Distal Deep Vein Thrombosis
- Study of Apixaban in Patients Receiving Hemodiafiltration
- Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage
- Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis
- Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients
- Rivaroxaban in Type 2 Myocardial Infarctions
- Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis
- Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
- Rivaroxaban or Aspirin in Patients With CHD & GD Undergoing PCI
- Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
- Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.
- COVID-19 Antithrombotic Rivaroxaban Evaluation
- Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
- Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions
- Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions
- A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men
- Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
- A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants
- Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19
- Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
- Bioequivalence of Xaroban 20mg (Rivaroxaban) Tablet and Xarelto 20mg (Rivaroxaban) Tablet Under Fed Conditions
- Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial
- NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
- COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
- Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)
- Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.
- Study of Ciraparantag for Reversal of Anticoagulation Induced by Apixaban or Rivaroxaban in Healthy Adults
- Rivaroxaban vs. Warfarin in CVT Treatment
- Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects
- Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects
- A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
- A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)
- Postoperative Thrombosis Prevention in Patients With CD
- Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers
- Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19
- Anticoagulation Therapy After Splenectomy in Cirrhosis Patient
- Protective Effect of Aspirin on COVID-19 Patients
- Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)
- Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial
- Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports
- The Direct Oral Anticoagulation Versus Warfarin After Cardiac Surgery Trial
- Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)
- Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
- Prophylactic Anticoagulation for Catheter-related Thrombosis
- Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery
- DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease
- Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation With Stabilized Coronary Artery Disease
- Pharmacokinetics of Rivaroxaban After Bariatric Surgery
- Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban
- Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease
- A Multi-center RCT Trial on Prognosis of Patients With Anticoagulation and DAPT Therapy After LAAC
- Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS
- VTE Prevention Following Total Hip and Knee Arthroplasty
- AntiCoagulants and COGnition
- Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study
- Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
- Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
- DUAL Antithrombotic Therapy in Patients With AF and ACS
- Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
- DOAC Versus VKA After Cardiac Surgery
- PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
- Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease
- MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
- Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi
- RIvoraxaban in Mitral Stenosis
- Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamic of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers
- Oral Anticoagulation in Hemodialysis
- Rivaroxaban Hypericum Trial
- A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation
- Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)
- Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS
- Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant
- Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation
- Efficacy Comparison of Warfarin Versus Rivaroxaban CVT
- Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies
- Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
- RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome
- Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation
- Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- Surgical Revascularization Outcomes After Oral Anticoagulation or Antiplatelets
- Pharmacokinetics of Simvastatin Post Laparoscopic Sleeve Gastrectomy (LSG)
- Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis
- Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery
- Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
- Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
- Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study
- ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy.
- Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis
- Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome
- The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention
- A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
- Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin
- REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.
- Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients
- Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD
- Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
- Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
- Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV
- Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
- Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis
- Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants
- Study of Rivaroxaban for CeREbral Venous Thrombosis
- Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
- Start or STop Anticoagulants Randomised Trial (SoSTART)
- A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
- Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)
- Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.
- Anticoagulation for Advanced Cirrhotic Patients After TIPS
- Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation
- Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban
- Rivaroxaban or Aspirin for Biological Aortic Prosthesis
- Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury
- Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants
- Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists
- The Effect of Cinnamon Cassia on Diabetes Control and Cardiometabolic Risk Factors in Adults With Type 2 Diabetes Mellitus
- ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)
- Rivaroxaban for Patients With Antiphospholipid Syndrome
- Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy
- Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
- Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF)
- Rivaroxaban in Mechanical Valves: RMV Study
- Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study
- Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist
- Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
- Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure
- Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
- PK of Rivaroxaban in Bariatric Patients - Extension
- INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority
- INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority
- RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
- Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
- Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients
- Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study
- Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S
- Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
- Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
- Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
- A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
- Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis
- Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs.
- Real-world Comparative Effectiveness of Rivaroxaban Versus VKA
- DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
- Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
- Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
- Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects
- Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis
- Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study
- APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
- Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study
- Atrial Fibrillation Patient Preference Study
- Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients
- A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
- Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
- Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation
- Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates
- A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants
- Comparison of Bleeding Risk Between Rivaroxaban and Apixaban
- Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)
- Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes
- A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
- Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
- Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban
- Pleotropic Effect of New Oral Anticoagulants
- Bioequivalence Study of Rivaroxaban
- Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects
- XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis
- Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
- Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children
- Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study
- Real-Life Evidence on Stroke Prevention in SPAF
- Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
- The Blood Saving Effect of Tranexamic Acid in Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis
- Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty
- Rivaroxaban in Bariatric Surgery
- Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation
- Blood-sparing During Hip Prosthesis Surgery With Exacyl® in Patients Treated With Rivaroxaban
- PROphylaxis in NOn Major Orthopaedic Surgery
- Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF
- Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty
- Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
- Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditi
- Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
- Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran
- Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
- EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
- RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial
- A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
- A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
- Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over
- Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention
- Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty
- Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
- Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain
- Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia
- Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance
- EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis
- Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy
- Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
- Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Cardiovascular Disease
- Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation
- Rivaroxaban in Thrombotic Antiphospholipid Syndrome
- Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.
- Rivaroxaban Anticoagulation for Superficial Vein Thrombosis
- Rivaroxaban for Antiphospholipid Antibody Syndrome
- A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
- BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies
- Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.
- The Effect of Rivaroxaban in Sickle Cell Disease
- Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification
- Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
- Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery
- Evaluation of Wound Drainage After Knee or Hip Arthroplasty
- Dose-finding of Rivaroxaban in Hemodialysis
- Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
- Registry for Estimation of Warfarin and Rivaroxaban in Atrial Fibrillation Patients With Coronary Stent Implantation
- TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
- Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
- Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer
- Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study
- A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers
- Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
- Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)
- Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
- Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events
- A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
- Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet
- Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter
- A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
- Antithrombotic Triple Therapy in Humans
- Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication
- Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication
- Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region
- Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
- Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia
- Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
- A Prospective Pharmacodynamic Study of Rivaroxaban
- A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
- Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty
- Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2)
- Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
- Oral Rivaroxaban in Children With Venous Thrombosis
- Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
- Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
- A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers
- Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy
- Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban
- Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
- Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
- Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
- Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan
- Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
- Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients
- Switching Study From Warfarin to Rivaroxaban
- Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
- Reversal of the Antithrombotic Action of New Oral Anticoagulants
- Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
- Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention
- Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban
- Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
- A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers
- A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)
- Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
- A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function
- Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
- Dose-confirmatory Bridging Study in Total Knee Replacement
- Dose-confirmatory Bridging Study in Total Hip Replacement
- Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
- Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
- An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
- Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
- Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
- Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
- Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study
- Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study
- Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study
- An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
- Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)
- Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
Clinical trials list
click for details